{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:51:17Z","timestamp":1791251477584,"version":"4.1.0"},"reference-count":129,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,11,22]],"date-time":"2014-11-22T00:00:00Z","timestamp":1416614400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1007\/s40264-014-0239-7","type":"journal-article","created":{"date-parts":[[2014,12,2]],"date-time":"2014-12-02T13:05:16Z","timestamp":1417525516000},"page":"33-54","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":140,"title":["The Comparative Efficacy and Safety of the Angiotensin Receptor Blockers in the Management of Hypertension and Other Cardiovascular Diseases"],"prefix":"10.1007","volume":"38","author":[{"given":"Hazel Mae A.","family":"Abraham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Michael","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William B.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,11,22]]},"reference":[{"key":"239_CR1","unstructured":"Data from the National Health and Nutrition Examination Survey (NHANES). National Center for Health Statistics. Health, United States, 2013: with special feature on prescription drugs. Hyattsville. 2014. http:\/\/www.cdc.gov\/nchs\/data\/hus\/hus13.pdf#064 . Accessed 19 July 2014."},{"key":"239_CR2","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","volume":"289","author":"AV Chobanian","year":"2003","unstructured":"Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 2003;289:2560\u201372.","journal-title":"JAMA"},{"key":"239_CR3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","volume":"311","author":"PA James","year":"2014","unstructured":"James PA, Oparil S, Carter BL, et al. Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507\u201320.","journal-title":"JAMA"},{"key":"239_CR4","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/jch.12237","volume":"16","author":"WB White","year":"2014","unstructured":"White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich). 2014;16:14\u201326.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"239_CR5","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","volume":"34","author":"G Mancia","year":"2013","unstructured":"Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH\/ESC guidelines for the management of arterial hypertension. Eur Heart J. 2013;34:2159\u2013219.","journal-title":"Eur Heart J"},{"key":"239_CR6","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.cjca.2014.02.002","volume":"30","author":"K Dasgupta","year":"2014","unstructured":"Dasgupta K, Quinn RR, Zarnke KB, et al. The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol. 2014;30:485\u2013501.","journal-title":"Can J Cardiol"},{"issue":"Suppl\u00a01","key":"239_CR7","doi-asserted-by":"crossref","first-page":"s11","DOI":"10.2337\/dc13-S011","volume":"36","author":"American Diabetes Association","year":"2013","unstructured":"American Diabetes Association. Standards of medical care in diabetes\u20142013. Diabetes Care. 2013;36(Suppl\u00a01):s11\u201366.","journal-title":"Diabetes Care"},{"key":"239_CR8","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S1470-2045(10)70106-6","volume":"11","author":"I Sipahi","year":"2010","unstructured":"Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 2010;11:627\u201336.","journal-title":"Lancet Oncol"},{"key":"239_CR9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(10)70260-6","volume":"12","author":"S Bangalore","year":"2011","unstructured":"Bangalore S, Kumar S, Kjeldsen SE, et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol. 2011;12:65\u201382.","journal-title":"Lancet Oncol"},{"key":"239_CR10","doi-asserted-by":"crossref","unstructured":"Pasternak B, Svanstr\u00f6m H, Callr\u00e9us T, Melbye M, Hviid A. Use of angiotensin receptor blockers and the risk of cancer. Circulation. 2011;123:1729\u201336.","DOI":"10.1161\/CIRCULATIONAHA.110.007336"},{"key":"239_CR11","volume-title":"Philadelphia","author":"GM Brenner","year":"2013","unstructured":"Brenner GM, Pharmacology Stevens CW, Edition Fourth. Philadelphia. Pennsylvania: Saunders; 2013."},{"key":"239_CR12","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.pcad.2004.04.005","volume":"47","author":"GB Appel","year":"2004","unstructured":"Appel GB, Appel AS. Angiotensin\u00a0II receptor antagonists: role in hypertension, cardiovascular disease, and renoprotection. Prog Cardiovasc Dis. 2004;47:105\u201315.","journal-title":"Prog Cardiovasc Dis"},{"issue":"12 Pt 3","key":"239_CR13","doi-asserted-by":"crossref","first-page":"205S","DOI":"10.1016\/S0895-7061(99)00103-X","volume":"12","author":"MR Weir","year":"1999","unstructured":"Weir MR, Dzau VJ. The renin\u2013angiotensin\u2013aldosterone system: a specific target for hypertension management. Am J Hypertens. 1999;12(12 Pt 3):205S\u201313S.","journal-title":"Am J Hypertens"},{"issue":"Suppl\u00a01","key":"239_CR14","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1038\/sj.jhh.1000991","volume":"14","author":"ZH Israili","year":"2000","unstructured":"Israili ZH. Clinical pharmacokinetics of angiotensin\u00a0II (AT1) receptor blockers in hypertension. J Hum Hypertens. 2000;14(Suppl\u00a01):S73\u201386.","journal-title":"J Hum Hypertens"},{"issue":"8A","key":"239_CR15","doi-asserted-by":"crossref","first-page":"3C","DOI":"10.1016\/S0002-9149(01)01538-7","volume":"87","author":"HR Brunner","year":"2001","unstructured":"Brunner HR. Experimental and clinical evidence that angiotensin\u00a0II is an independent risk factor for cardiovascular disease. Am J Cardiol. 2001;87(8A):3C\u20139C.","journal-title":"Am J Cardiol"},{"key":"239_CR16","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJM199104183241605","volume":"324","author":"MH Alderman","year":"1991","unstructured":"Alderman MH, Madhavan S, Ooi WL, et al. Association of the renin\u2013sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med. 1991;324:1098\u2013104.","journal-title":"N Engl J Med"},{"key":"239_CR17","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1161\/01.CIR.103.6.904","volume":"103","author":"M Burnier","year":"2001","unstructured":"Burnier M. Angiotensin\u00a0II, type\u00a01 receptor blockers. Circulation. 2001;103:904\u201312.","journal-title":"Circulation"},{"key":"239_CR18","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1161\/HYPERTENSIONAHA.113.02522","volume":"63","author":"D Lauer","year":"2014","unstructured":"Lauer D, Slavic S, Sommerfeld M, et al. Angiotensin type\u00a02 receptor stimulation ameliorates left ventricular fibrosis and dysfunction via regulation of tissue inhibitor of matrix metalloproteinase\u00a01\/matrix metalloproteinase\u00a09 axis and transforming growth factor\u00a0\u03b21 in the rat heart. Hypertension. 2014;63:e60\u20137.","journal-title":"Hypertension"},{"key":"239_CR19","doi-asserted-by":"crossref","unstructured":"McClellan KJ, Balfour JA. Eprosartan. Drugs 1998;55:713\u2013720.","DOI":"10.2165\/00003495-199855050-00011"},{"key":"239_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1470320310370852","volume":"12","author":"S Miura","year":"2011","unstructured":"Miura S, Karnik SS, Saku K. Review: Angiotensin\u00a0II type\u00a01 receptor blockers: class effects versus molecular effects. J Renin Angiotensin Aldosterone Syst. 2011;12:1\u20137.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"239_CR21","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1161\/HYPERTENSIONAHA.110.163402","volume":"57","author":"WB White","year":"2011","unstructured":"White WB, Weber MA, et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and\u00a02 hypertension. Hypertension. 2011;57:413\u201320.","journal-title":"Hypertension"},{"key":"239_CR22","unstructured":"Cozaar: prescribing information. Updated 2013. Merck Sharp & Dohme Corp., Whitehouse Station. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/020386s060lbl.pdf . Accessed 1 June 2014."},{"key":"239_CR23","unstructured":"Diovan: prescribing information. Updated 2014. Novartis Pharmaceuticals Corp., East Hanover. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/020665s034s035lbl.pdf . Accessed 1 June 2014."},{"key":"239_CR24","unstructured":"Atacand: prescribing information. Updated 2013. Takeda Pharmaceutical Company, Wilmington. http:\/\/www1.astrazeneca-us.com\/pi\/Atacand.pdf . Accessed 1 June 2014."},{"key":"239_CR25","unstructured":"Avapro: prescribing information. Updated 2014. Sanofi-Aventis, Bridgewater. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/020757s064lbl.pdf . Accessed 1 June 2014."},{"key":"239_CR26","unstructured":"Benicar: prescribing information. Updated 2014. Daiichi Sankyo, Parsippany. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/021286s031lbl.pdf . Accessed 1 June 2014."},{"key":"239_CR27","unstructured":"Micardis: prescribing information. Updated 2012. Boehringer Ingelheim, Ridgefield. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020850s033lbl.pdf . Accessed 1 June 2014."},{"key":"239_CR28","unstructured":"Teveten: prescribing information. Updated 2011. Abbott Laboratories, North Chicago. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/020738s026lbl.pdf . Accessed 1 June 2014."},{"key":"239_CR29","unstructured":"Edarbi: prescribing information. Updated 2011. Takeda Pharmaceutical Company, Deerfield. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/200796s000lbl.pdf . Accessed 1 June 2014."},{"key":"239_CR30","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1592\/phco.20.3.130.34788","volume":"20","author":"JC Song","year":"2000","unstructured":"Song JC, White CM. Pharmacologic, pharmacokinetic, and therapeutic differences among angiotensin\u00a0II receptor antagonists. Pharmacotherapy. 2000;20:130\u20139.","journal-title":"Pharmacotherapy"},{"issue":"Suppl\u00a02","key":"239_CR31","first-page":"S19","volume":"11","author":"R H\u00fcbner","year":"1997","unstructured":"H\u00fcbner R, H\u00f6gemann AM, Sunzel M, et al. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. J Hum Hypertens. 1997;11(Suppl\u00a02):S19\u201325.","journal-title":"J Hum Hypertens"},{"key":"239_CR32","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.2165\/00003495-200868090-00005","volume":"68","author":"LJ Scott","year":"2008","unstructured":"Scott LJ, McCormack PL. Olmesartan medoxomil a review of its use in the management of hypertension. Drugs. 2008;68:1239\u201372.","journal-title":"Drugs"},{"key":"239_CR33","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1291\/hypres.27.457","volume":"27","author":"G Derosa","year":"2004","unstructured":"Derosa G, Ragonesi PD, Mugellini A, Ciccarelli L, Fogari R. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type\u00a02 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens Res. 2004;27:457\u201364.","journal-title":"Hypertens Res"},{"key":"239_CR34","doi-asserted-by":"crossref","first-page":"311S","DOI":"10.1016\/S0895-7061(97)00391-9","volume":"10","author":"HR Brunner","year":"1997","unstructured":"Brunner HR. The new angiotensin\u00a0II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations. Am J Hypertens. 1997;10:311S\u20137S.","journal-title":"Am J Hypertens"},{"key":"239_CR35","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.2165\/00003495-200161100-00009","volume":"61","author":"M Sharpe","year":"2001","unstructured":"Sharpe M, Jarvis B, Goa KL. Telmisartan: a review of its use in hypertension. Drugs. 2001;61:1501\u201329.","journal-title":"Drugs"},{"key":"239_CR36","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1124\/dmd.106.012351","volume":"34","author":"C Chang","year":"2006","unstructured":"Chang C, Bahadduri PM, et al. Rapid identification of P-glycoprotein substrates and inhibitors. Drug Metab Dispos. 2006;34:1976\u201384.","journal-title":"Drug Metab Dispos"},{"key":"239_CR37","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.2165\/11319460-000000000-00000","volume":"69","author":"HR Black","year":"2009","unstructured":"Black HR, Bailey J, Zappe D, Samuel R. Valsartan: more than a decade of experience. Drugs. 2009;69:2393\u2013414.","journal-title":"Drugs"},{"key":"239_CR38","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/080370598437574","volume":"7","author":"OK Andersson","year":"1998","unstructured":"Andersson OK, Neldam S. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin\u00a0II antagonist, in comparison with losartan. Blood Press. 1998;7:53\u20139.","journal-title":"Blood Press"},{"key":"239_CR39","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S0895-7061(99)00142-9","volume":"12","author":"Y Lacourci\u00e8re","year":"1999","unstructured":"Lacourci\u00e8re Y, Asmar R. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan\/Losartan Study Investigators. Am J Hypertens. 1999;12:1181\u20137.","journal-title":"Am J Hypertens"},{"key":"239_CR40","first-page":"52","volume":"1","author":"AH Gradman","year":"1999","unstructured":"Gradman AH, Lewin A, Bowling BT, et al. Comparative effects of candesartan cilexetil and losartan in patients with systemic hypertension. Candesartan Versus Losartan Efficacy Comparison (CANDLE) Study Group. Heart Dis. 1999;1:52\u20137.","journal-title":"Heart Dis"},{"key":"239_CR41","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/S0149-2918(00)83062-3","volume":"22","author":"AJ Manolis","year":"2000","unstructured":"Manolis AJ, Grossman E, Jelakovic B, et al. Effects of losartan and candesartan monotherapy and losartan\/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators. Clin Ther. 2000;22:1186\u2013203.","journal-title":"Clin Ther"},{"key":"239_CR42","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/sj.jhh.1001205","volume":"15","author":"DG Vidt","year":"2001","unstructured":"Vidt DG, White WB, Ridley E, et al. A forced titration study of antihypertensive efficacy of candesartan cilexetil in comparison to losartan: CLAIM Study\u00a0II. J Hum Hypertens. 2001;15:475\u201380.","journal-title":"J Hum Hypertens"},{"key":"239_CR43","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2165\/00044011-200323070-00001","volume":"23","author":"HR Brunner","year":"2003","unstructured":"Brunner HR, Stumpe KO, Januszewicz A. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension. Clin Drug Invest. 2003;23:419\u201330.","journal-title":"Clin Drug Invest"},{"issue":"283\u201391","key":"239_CR44","first-page":"318","volume":"3","author":"S Oparil","year":"2001","unstructured":"Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel J. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich). 2001;3(283\u201391):318.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"239_CR45","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1524-6175.2007.06395.x","volume":"9","author":"TD Giles","year":"2007","unstructured":"Giles TD, Oparil S, Silfani TN, Wang A, Walker JF. Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension. J Clin Hypertens (Greenwich). 2007;9:187\u201395.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"239_CR46","doi-asserted-by":"crossref","unstructured":"Lee YT, Lee CM, Lin CS et al. A double-blind comparison of the efficacy and tolerability of telmisartan 40\u201380 mg vs. losartan 50\u2013100\u00a0mg in Taiwanese hypertensive patients. Int J Clin Pract (Suppl). 2004;145:40\u20135.","DOI":"10.1111\/j.1742-1241.2004.00409.x"},{"key":"239_CR47","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/sj.jhh.1000925","volume":"13","author":"J Mallion","year":"1999","unstructured":"Mallion J, Siche J, Lacourci\u00e8re Y. ABPM comparison of the antihypertensive profiles of the selective angiotensin\u00a0II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens. 1999;13:657\u201364.","journal-title":"J Hum Hypertens"},{"key":"239_CR48","unstructured":"Zhu JR1, Bai J, Cai NS et al. Efficacy and safety of telmisartan vs. losartan in control of mild-to-moderate hypertension: a multicentre, randomised, double-blind study. Int J Clin Pract (Suppl). 2004;145:46\u20139."},{"key":"239_CR49","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/00004872-200404000-00028","volume":"22","author":"C Calvo","year":"2004","unstructured":"Calvo C, Hermida RC, Ayala DE, Ruilope LM. Effects of telmisartan 80 mg and valsartan 160\u00a0mg on ambulatory blood pressure in patients with essential hypertension. J Hypertens. 2004;22:837\u201346.","journal-title":"J Hypertens"},{"key":"239_CR50","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.amjhyper.2004.02.016","volume":"17","author":"WB White","year":"2004","unstructured":"White WB, Lacourci\u00e8re Y, Davidai G. Effects of the angiotensin\u00a0II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period. Am J Hypertens. 2004;17:347\u201353.","journal-title":"Am J Hypertens"},{"key":"239_CR51","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0895-7061(97)00491-3","volume":"11","author":"K Kassler-Taub","year":"1998","unstructured":"Kassler-Taub K, Littlejohn T, Elliott W, Ruddy T, Adler E. Comparative efficacy of two angiotensin\u00a0II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan\/Losartan Study Investigators. Am J Hypertens. 1998;11:445\u201353.","journal-title":"Am J Hypertens"},{"key":"239_CR52","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/00126097-200204000-00008","volume":"7","author":"G Mancia","year":"2002","unstructured":"Mancia G, Korlipara K, van Rossum P, Villa G, Silvert B. An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin\u00a0II receptor antagonists, irbesartan and valsartan. Blood Press Monit. 2002;7:135\u201342.","journal-title":"Blood Press Monit"},{"key":"239_CR53","doi-asserted-by":"crossref","unstructured":"Sica D, White WB, Weber MA, et al. Comparison of the novel angiotensin\u00a0II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich). 2001;13:467\u201372.","DOI":"10.1111\/j.1751-7176.2011.00482.x"},{"key":"239_CR54","doi-asserted-by":"crossref","unstructured":"Bakris G, Gradman A, CLAIM Study Investigators, et al. Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study. J Clin Hypertens (Greenwich). 2001;3:16\u201321.","DOI":"10.1111\/j.1524-6175.2001.00826.x"},{"key":"239_CR55","first-page":"1123","volume":"16","author":"T Littlejohn","year":"2000","unstructured":"Littlejohn T, Mroczek W, Marbury T, VanderMaelen CP, Dubiel RF. A prospective, randomized, open-label trial comparing telmisartan 80\u00a0mg with valsartan 80\u00a0mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring. Can J Cardiol. 2000;16:1123\u201332.","journal-title":"Can J Cardiol"},{"key":"239_CR56","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S0895-7061(01)02201-4","volume":"14","author":"WB White","year":"2001","unstructured":"White WB, Anwar YA, Mansoor GA, Sica DA. Evaluation of the 24-hour blood pressure effects of eprosartan in patients with systemic hypertension. Am J Hypertens. 2001;14:1248\u201355.","journal-title":"Am J Hypertens"},{"key":"239_CR57","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1586\/14779072.1.1.43","volume":"1","author":"B Waeber","year":"2003","unstructured":"Waeber B. Combination therapy with ACE inhibitors\/angiotensin\u00a0II receptor antagonists and diuretics in hypertension. Expert Rev Cardiovasc Ther. 2003;1:43\u201350.","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"239_CR58","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1751-7176.2011.00512.x","volume":"13","author":"DA Sica","year":"2011","unstructured":"Sica DA, Carter B, Cushman W, Hamm L. Thiazide and loop diuretics. J Clin Hypertens (Greenwich). 2011;13:639\u201343.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"239_CR59","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/sj.jhh.1002140","volume":"21","author":"R Fogari","year":"2007","unstructured":"Fogari R, Zoppi A, Derosa G, et al. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens. 2007;21:220\u20134.","journal-title":"J Hum Hypertens"},{"key":"239_CR60","first-page":"85","volume":"7","author":"G B\u00f6nner","year":"2011","unstructured":"B\u00f6nner G, Landers B, Bramlage P. Candesartan cilexetil\/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple\u00a0T). Vasc Health Risk Manag. 2011;7:85\u201395.","journal-title":"Vasc Health Risk Manag"},{"key":"239_CR61","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/sj.jhh.1001317","volume":"16","author":"A Sachse","year":"2002","unstructured":"Sachse A, Verboom CN, J\u00e4ger B. Efficacy of eprosartan in combination with HCTZ in patients with essential hypertension. J Hum Hypertens. 2002;16:169\u201376.","journal-title":"J Hum Hypertens"},{"key":"239_CR62","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1185\/03007995.2011.644626","volume":"28","author":"D Rosenbaum","year":"2012","unstructured":"Rosenbaum D, Girerd X. Olmesartan medoxomil combined with hydrochlorothiazide improves 24-hour blood pressure control in moderate-to-severe hypertension. Curr Med Res Opin. 2012;28:179\u201386.","journal-title":"Curr Med Res Opin"},{"key":"239_CR63","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1291\/hypres.30.729","volume":"30","author":"T Saruta","year":"2007","unstructured":"Saruta T, Ogihara T, Matsuoka H, et al. Antihypertensive efficacy and safety of fixed-dose combination therapy with losartan plus hydrochlorothiazide in Japanese patients with essential hypertension. Hypertens Res. 2007;30:729\u201339.","journal-title":"Hypertens Res"},{"key":"239_CR64","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1524-6175.2004.03808.x","volume":"6","author":"CM Salerno","year":"2004","unstructured":"Salerno CM, Demopoulos L, Mukherjee R, Gradman AH. Combination angiotensin receptor blocker\/hydrochlorothiazide as initial therapy in the treatment of patients with severe hypertension. J Clin Hypertens (Greenwich). 2004;6:614\u201320.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"239_CR65","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/sj.jhh.1002293","volume":"22","author":"JM Neutel","year":"2008","unstructured":"Neutel JM, Franklin SS, Lapuerta P, et al. A comparison of the efficacy and safety of irbesartan\/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension. J Hum Hypertens. 2008;22:266\u201374.","journal-title":"J Hum Hypertens"},{"key":"239_CR66","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1185\/03007990802271946","volume":"24","author":"DA Calhoun","year":"2008","unstructured":"Calhoun DA, Glazer RD, Pettyjohn FS, et al. Efficacy and tolerability of combination therapy with valsartan\/hydrochlorothiazide in the initial treatment of severe hypertension. Curr Med Res Opin. 2008;24:2303\u201311.","journal-title":"Curr Med Res Opin"},{"key":"239_CR67","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00045391-200203000-00005","volume":"9","author":"Y Lacourci\u00e8re","year":"2002","unstructured":"Lacourci\u00e8re Y, Martin K. Comparison of a fixed-dose combination of 40\u00a0mg telmisartan plus 12.5\u00a0mg hydrochlorothiazide with 40\u00a0mg telmisartan in the control of mild to moderate hypertension. Am J Ther. 2002;9:111\u20137.","journal-title":"Am J Ther"},{"key":"239_CR68","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/sj.jhh.1001267","volume":"15","author":"Y Lacourci\u00e8re","year":"2001","unstructured":"Lacourci\u00e8re Y, Tytus R, O\u2019Keefe D, et al. Efficacy and tolerability of a fixed-dose combination of telmisartan plus hydrochlorothiazide in patients uncontrolled with telmisartan monotherapy. J Hum Hypertens. 2001;15:763\u201370.","journal-title":"J Hum Hypertens"},{"key":"239_CR69","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/j.1751-7176.2008.08187.x","volume":"10","author":"S Neldam","year":"2008","unstructured":"Neldam S, Edwards C. Results of increasing doses of hydrochlorothiazide in combination with an angiotensin receptor blocker in patients with uncontrolled hypertension. J Clin Hypertens (Greenwich). 2008;10:612\u20138.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"239_CR70","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1751-7176.2012.00616.x","volume":"14","author":"D Sica","year":"2012","unstructured":"Sica D, Bakris GL, White WB, et al. Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study. J Clin Hypertens (Greenwich). 2012;14:284\u201392.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"239_CR71","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.clinthera.2008.04.002","volume":"30","author":"SG Chrysant","year":"2008","unstructured":"Chrysant SG, Melino M, Karki S, Lee J, Heyrman R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther. 2008;30:587\u2013604.","journal-title":"Clin Ther"},{"key":"239_CR72","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.clinthera.2007.03.018","volume":"29","author":"T Philipp","year":"2007","unstructured":"Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther. 2007;29:563\u201380.","journal-title":"Clin Ther"},{"key":"239_CR73","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/jhh.2008.153","volume":"23","author":"JM Flack","year":"2009","unstructured":"Flack JM, Calhoun DA, Satlin L, et al. Efficacy and safety of initial combination therapy with amlodipine\/valsartan compared with amlodipine monotherapy in black patients with stage\u00a02 hypertension: the EX-STAND study. J Hum Hypertens. 2009;23:479\u201389.","journal-title":"J Hum Hypertens"},{"key":"239_CR74","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1751-7176.2012.00595.x","volume":"14","author":"JM Neutel","year":"2012","unstructured":"Neutel JM, Mancia G, Black HR, et al. Single-pill combination of telmisartan\/amlodipine in patients with severe hypertension: results from the TEAMSTA severe HTN study. J Clin Hypertens (Greenwich). 2012;14:206\u201315.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"239_CR75","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2165\/11597410-000000000-00000","volume":"12","author":"BK Hong","year":"2012","unstructured":"Hong BK, Park CG, Kim KS, et al. Comparison of the efficacy and safety of fixed-dose amlodipine\/losartan and losartan in hypertensive patients inadequately controlled with losartan: a randomized, double-blind, multicenter study. Am J Cardiovasc Drugs. 2012;12:189\u201395.","journal-title":"Am J Cardiovasc Drugs"},{"key":"239_CR76","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.clinthera.2012.02.015","volume":"34","author":"H Rakugi","year":"2012","unstructured":"Rakugi H, Ogihara T, Miyata Y, Sasai K, Totsuka N. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2012;34:838\u201348.","journal-title":"Clin Ther"},{"key":"239_CR77","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1185\/03007995.2013.803057","volume":"29","author":"DA Calhoun","year":"2013","unstructured":"Calhoun DA, Lacourci\u00e8re Y, Crikelair N, Jia Y, Glazer RD. Effects of demographics on the antihypertensive efficacy of triple therapy with amlodipine, valsartan, and hydrochlorothiazide for moderate to severe hypertension. Curr Med Res Opin. 2013;29:901\u201310.","journal-title":"Curr Med Res Opin"},{"key":"239_CR78","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"288","author":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group","year":"2002","unstructured":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981\u201397.","journal-title":"JAMA"},{"key":"239_CR79","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/HYPERTENSIONAHA.109.131300","volume":"54","author":"DA Calhoun","year":"2009","unstructured":"Calhoun DA, Lacourci\u00e8re Y, Chiang YT, Glazer RD. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension. 2009;54:32\u20139.","journal-title":"Hypertension"},{"key":"239_CR80","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.clinthera.2010.07.008","volume":"32","author":"S Oparil","year":"2010","unstructured":"Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther. 2010;32:1252\u201369.","journal-title":"Clin Ther"},{"key":"239_CR81","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/jch.12133","volume":"15","author":"EM Roth","year":"2013","unstructured":"Roth EM, Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Olmesartan\/amlodipine\/hydrochlorothiazide in obese participants with hypertension: a TRINITY subanalysis. J Clin Hypertens (Greenwich). 2013;15:584\u201392.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"239_CR82","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/BF03261832","volume":"12","author":"SG Chrysant","year":"2012","unstructured":"Chrysant SG, Littlejohn T 3rd, Izzo JL Jr, et al. Triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in black and non-black study participants with hypertension: the TRINITY randomized, double-blind, 12-week, parallel-group study. Am J Cardiovasc Drugs. 2012;12:233\u201343.","journal-title":"Am J Cardiovasc Drugs"},{"key":"239_CR83","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jash.2011.09.003","volume":"6","author":"SG Chrysant","year":"2012","unstructured":"Chrysant SG, Izzo JL Jr, Kereiakes DJ, Littlejohn T 3rd, Oparil S, et al. Efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in study participants with hypertension and diabetes: a subpopulation analysis of the TRINITY study. J Am Soc Hypertens. 2012;6:132\u201341.","journal-title":"J Am Soc Hypertens"},{"key":"239_CR84","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/bmj.f360","volume":"346","author":"H Makani","year":"2013","unstructured":"Makani H, Bangalore S, Desouza KA, Shah A, Messerli FH. Efficacy and safety of dual blockade of the renin\u2013angiotensin system: meta-analysis of randomised trials. BMJ. 2013;346:360.","journal-title":"BMJ"},{"key":"239_CR85","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","volume":"372","author":"JF Mann","year":"2008","unstructured":"Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547\u201353.","journal-title":"Lancet"},{"key":"239_CR86","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","volume":"367","author":"HH Parving","year":"2012","unstructured":"Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type\u00a02 diabetes. N Engl J Med. 2012;367:2204\u201313.","journal-title":"N Engl J Med"},{"key":"239_CR87","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","volume":"364","author":"S Yusuf","year":"2004","unstructured":"Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case\u2013control study. Lancet. 2004;364:937\u201352.","journal-title":"Lancet"},{"key":"239_CR88","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","volume":"359","author":"B Dahl\u00f6f","year":"2002","unstructured":"Dahl\u00f6f B, Devereux RB, Kjeldsen SE, LIFE Study Group, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995\u20131003.","journal-title":"Lancet"},{"key":"239_CR89","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S0895-7061(03)00904-X","volume":"16","author":"S Julius","year":"2003","unstructured":"Julius S, Kjeldsen SE, Brunner H, et al. VALUE trial: long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am J Hypertens. 2003;16:544\u20138.","journal-title":"Am J Hypertens"},{"key":"239_CR90","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/00004872-200305000-00011","volume":"21","author":"H Lithell","year":"2003","unstructured":"Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21:875\u201386.","journal-title":"J Hypertens"},{"key":"239_CR91","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(08)61193-9","volume":"372","author":"S Yusuf","year":"2008","unstructured":"Yusuf S, Teo K, Anderson C, Pogue J, et al. Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372:1174\u201383.","journal-title":"Lancet"},{"key":"239_CR92","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","volume":"345","author":"HH Parving","year":"2001","unstructured":"Parving HH, Lehnert H, Br\u00f6chner-Mortensen J, Gomis R, Andersen S, Arner P, Irbesartan in Patients with Type\u00a02 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type\u00a02 diabetes. N Engl J Med. 2001;345:870\u20138.","journal-title":"N Engl J Med"},{"key":"239_CR93","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1161\/01.CIR.0000024416.33113.0A","volume":"106","author":"G Viberti","year":"2002","unstructured":"Viberti G, Wheeldon NM, Microalbuminuria Reduction with Valsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type\u00a02 diabetes mellitus: a blood pressure-independent effect. Circulation. 2002;106:672\u20138.","journal-title":"Circulation"},{"key":"239_CR94","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type\u00a02 diabetes and nephropathy. N Engl J Med. 2001;345:861\u20139.","journal-title":"N Engl J Med"},{"key":"239_CR95","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type\u00a02 diabetes. N Engl J Med. 2001;345:851\u201360.","journal-title":"N Engl J Med"},{"key":"239_CR96","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","volume":"355","author":"B Pitt","year":"2000","unstructured":"Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial\u2014the Losartan Heart Failure Survival Study ELITE\u00a0II. Lancet. 2000;355:1582\u20137.","journal-title":"Lancet"},{"key":"239_CR97","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","volume":"349","author":"MA Pfeffer","year":"2003","unstructured":"Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893\u2013906.","journal-title":"N Engl J Med"},{"key":"239_CR98","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","volume":"360","author":"K Dickstein","year":"2002","unstructured":"Dickstein K, Kjekshus J, OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin\u00a0II Antagonist Losartan. Lancet. 2002;360:752\u201360.","journal-title":"Lancet"},{"key":"239_CR99","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","volume":"362","author":"MA Pfeffer","year":"2003","unstructured":"Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362:759\u201366.","journal-title":"Lancet"},{"key":"239_CR100","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","volume":"362","author":"CB Granger","year":"2003","unstructured":"Granger CB, McMurray JJ, Yusuf S, CHARM Investigators and Committees, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362:772\u20136.","journal-title":"Lancet"},{"key":"239_CR101","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","volume":"362","author":"JJ McMurray","year":"2003","unstructured":"McMurray JJ, Ostergren J, Swedberg K, CHARM Investigators and Committees, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362:767\u201371.","journal-title":"Lancet"},{"key":"239_CR102","doi-asserted-by":"crossref","unstructured":"Yusuf S, Pfeffer MA, Swedberg K, CHARM Investigators and Committees, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet. 2003;362:777\u201381.","DOI":"10.1016\/S0140-6736(03)14285-7"},{"key":"239_CR103","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","volume":"345","author":"JN Cohn","year":"2001","unstructured":"Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667\u201375.","journal-title":"N Engl J Med"},{"key":"239_CR104","doi-asserted-by":"crossref","unstructured":"Massie BM, Carson PE, McMurray JJ, I-PRESERVE Investigators, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456\u201367.","DOI":"10.1056\/NEJMoa0805450"},{"key":"239_CR105","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/0895-4356(94)00231-E","volume":"48","author":"LE Visser","year":"1995","unstructured":"Visser LE, Stricker BH, van der Velden J, Paes AH, Bakker A. Angiotensin converting enzyme inhibitor associated cough: a population-based case\u2013control study. J Clin Epidemiol. 1995;48:851\u20137.","journal-title":"J Clin Epidemiol"},{"key":"239_CR106","doi-asserted-by":"crossref","first-page":"234","DOI":"10.7326\/0003-4819-117-3-234","volume":"117","author":"ZH Israili","year":"1992","unstructured":"Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy: a review of the literature and pathophysiology. Ann Intern Med. 1992;117:234\u201342.","journal-title":"Ann Intern Med"},{"key":"239_CR107","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/BF03261835","volume":"12","author":"D Caldeira","year":"2012","unstructured":"Caldeira D, David C, Sampaio C. Tolerability of angiotensin-receptor blockers in patients with intolerance to angiotensin-converting enzyme inhibitors: a systematic review and meta-analysis. Am J Cardiovasc Drugs. 2012;12:263\u201377.","journal-title":"Am J Cardiovasc Drugs"},{"key":"239_CR108","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.mayocp.2012.06.003","volume":"87","author":"A Rubio-Tapia","year":"2012","unstructured":"Rubio-Tapia A, Herman ML, Ludvigsson JF, et al. Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc. 2012;87:732\u20138.","journal-title":"Mayo Clin Proc"},{"key":"239_CR109","unstructured":"FDA Drug Safety Communication: FDA approves label changes to include intestinal problems (sprue-like enteropathy) linked to blood pressure medicine olmesartan medoxomil. http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM359496.pdf . Accessed 30 Sept 2014."},{"key":"239_CR110","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.mayocp.2014.05.012","volume":"89","author":"R Greywoode","year":"2014","unstructured":"Greywoode R, Braunstein E, Arguelles-Grande C, et al. Olmesartan, other antihypertensives, and chronic diarrhea among patients undergoing endoscopic procedures: a case\u2013control study. Mayo Clin Proc. 2014;89:1239\u201343.","journal-title":"Mayo Clin Proc"},{"key":"239_CR111","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s00380-012-0246-5","volume":"28","author":"W Fujiwara","year":"2013","unstructured":"Fujiwara W, Izawa H, Ukai G, et al. Low dose of hydrochlorothiazide, in combination with angiotensin receptor blocker, reduces blood pressure effectively without adverse effect on glucose and lipid profiles. Heart Vessel. 2013;28:316\u201322.","journal-title":"Heart Vessel"},{"key":"239_CR112","first-page":"761","volume":"7","author":"T Mengden","year":"2011","unstructured":"Mengden T, H\u00fcbner R, Bramlage P. Office and ambulatory blood pressure control with a fixed-dose combination of candesartan and hydrochlorothiazide in previously uncontrolled hypertensive patients: results of CHILI\u00a0CU Soon. Vasc Health Risk Manag. 2011;7:761\u20139.","journal-title":"Vasc Health Risk Manag"},{"key":"239_CR113","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2165\/11536710-000000000-00000","volume":"30","author":"R Fogari","year":"2010","unstructured":"Fogari R, Taddei S, Holm-Bentzen M, et al. Efficacy and safety of olmesartan medoxomil 40\u00a0mg\/hydrochlorothiazide 12.5\u00a0mg combination therapy versus olmesartan medoxomil 40\u00a0mg monotherapy in patients with moderate to severe hypertension. Clin Drug Invest. 2010;30:581\u201397.","journal-title":"Clin Drug Invest"},{"key":"239_CR114","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1751-7176.2009.00109.x","volume":"11","author":"P Lapuerta","year":"2009","unstructured":"Lapuerta P, Franklin S. The risks and benefits of initial irbesartan\/hydrochlorothiazide combination therapy in patients with severe hypertension. J Clin Hypertens. 2009;11:277\u201383.","journal-title":"J Clin Hypertens"},{"key":"239_CR115","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.clinthera.2007.01.007","volume":"29","author":"JL Pool","year":"2007","unstructured":"Pool JL, Glazer R, Weinberger M, et al. Comparison of valsartan\/hydrochlorothiazide combination therapy at doses up to 320\/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. Clin Ther. 2007;29:61\u201373.","journal-title":"Clin Ther"},{"key":"239_CR116","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1524-6175.2007.06415.x","volume":"9","author":"M Weir","year":"2007","unstructured":"Weir M, Crikelair N, Levy D. Evaluation of the dose response with valsartan and valsartan\/hydrochlorothiazide in patients with essential hypertension. J Clin Hypertens. 2007;9:103\u201312.","journal-title":"J Clin Hypertens"},{"key":"239_CR117","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1751-7176.2008.08259.x","volume":"10","author":"WB White","year":"2008","unstructured":"White WB, Calhoun D, Samuel R, et al. Improving blood pressure control: increase the dose of diuretic or switch to a fixed-dose angiotensin receptor blocker\/diuretic? The Valsartan Hydrochlorothiazide Diuretic for Initial Control and Titration to Achieve Optimal Therapeutic Effect (Val-DICTATE) trial. J Clin Hypertens (Greenwich). 2008;10:450\u20138.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"239_CR118","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1161\/CIRCULATIONAHA.105.594986","volume":"114","author":"MH Strauss","year":"2006","unstructured":"Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB\u2013MI paradox. Circulation. 2006;114:838\u201354.","journal-title":"Circulation"},{"key":"239_CR119","doi-asserted-by":"crossref","unstructured":"Haller H, Ito S, Izzo JL Jr, Januszewicz A, ROADMAP Trial Investigators, et al. Olmesartan for the delay or prevention of microalbuminuria in type\u00a02 diabetes. N Engl J Med. 2011;364:907\u201317.","DOI":"10.1056\/NEJMoa1007994"},{"key":"239_CR120","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1007\/s00125-011-2325-z","volume":"54","author":"E Imai","year":"2011","unstructured":"Imai E, Chan JC, Ito S, et al. Effects of olmesartan on renal and cardiovascular outcomes in type\u00a02 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia. 2011;54:2978\u201386.","journal-title":"Diabetologia"},{"key":"239_CR121","unstructured":"FDA Drug Safety Communication. FDA review of cardiovascular risks for diabetics taking hypertension drug olmesartan not conclusive; label updates required. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm402323.htm . Accessed 30 Sept 2014."},{"key":"239_CR122","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/sj.jhh.1001931","volume":"20","author":"BM Cheung","year":"2006","unstructured":"Cheung BM, Cheung GT, Lauder IJ, Lau CP, Kumana CR. Meta-analysis of large outcome trials of angiotensin receptor blockers in hypertension. J Hum Hypertens. 2006;20:37\u201343.","journal-title":"J Hum Hypertens"},{"key":"239_CR123","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1093\/eurheartj\/ehi445","volume":"26","author":"P Verdecchia","year":"2005","unstructured":"Verdecchia P, Angeli F, Gattobigio R, Reboldi GP. Do angiotensin\u00a0II receptor blockers increase the risk of myocardial infarction? Eur Heart J. 2005;26:2381\u20136.","journal-title":"Eur Heart J"},{"key":"239_CR124","doi-asserted-by":"crossref","unstructured":"McDonald MA, Simpson SH, Ezekowitz JA, Gyenes G, Tsuyuki RT. Angiotensin receptor blockers and risk of myocardial infarction: systematic review. BMJ. 2005;331:873.","DOI":"10.1136\/bmj.38595.518542.3A"},{"key":"239_CR125","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1097\/01.hjh.0000194114.12228.16","volume":"23","author":"M Volpe","year":"2005","unstructured":"Volpe M, Mancia G, Trimarco B. Angiotensin\u00a0II receptor blockers and myocardial infarction: deeds and misdeeds. J Hypertens. 2005;23:2113\u20138.","journal-title":"J Hypertens"},{"key":"239_CR126","doi-asserted-by":"crossref","first-page":"d2234","DOI":"10.1136\/bmj.d2234","volume":"342","author":"S Bangalore","year":"2011","unstructured":"Bangalore S, Kumar S, Wetterslev J, Messerli FH. Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147\u00a0020 patients from randomised trials. BMJ. 2011;342:d2234.","journal-title":"BMJ"},{"key":"239_CR127","doi-asserted-by":"crossref","first-page":"e2697","DOI":"10.1136\/bmj.e2697","volume":"344","author":"K Bhaskaran","year":"2012","unstructured":"Bhaskaran K, Douglas I, Evans S, van Staa T, Smeeth L. Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database. BMJ. 2012;344:e2697.","journal-title":"BMJ"},{"key":"239_CR128","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/S0140-6736(14)60614-0","volume":"383","author":"TD Giles","year":"2014","unstructured":"Giles TD, Weber MA, Basile J, et al. Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomized, multicenter study. Lancet. 2014;383:1889\u201398.","journal-title":"Lancet"},{"key":"239_CR129","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1056\/NEJMoa0804593","volume":"359","author":"S Yusuf","year":"2008","unstructured":"Yusuf S, Diener H, Sacco RL, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008;359:1225\u201337.","journal-title":"N Engl J Med"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-014-0239-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-014-0239-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-014-0239-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,17]],"date-time":"2019-08-17T22:35:09Z","timestamp":1566081309000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-014-0239-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,22]]},"references-count":129,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["239"],"URL":"https:\/\/doi.org\/10.1007\/s40264-014-0239-7","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,22]]}}}